Platinum neurotoxicity pharmacogenetics

Molecular Cancer Therapeutics

Volumn 8, Issue 1, 2009, Pages 10-16

  McWhinney, Sarah R ^a,b   Goldberg, Richard M ^a,b,c   McLeod, Howard L ^a,b,c  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b University of North Carolina   (United States)

^c UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 AMINO 4 (METHYLSULFONYL)BUTYRYLGLUTAMYLHISTIDYLPHENYLALANYL DEXTRO LYSYLPHENYLALANINE; ALPHA TOCOPHEROL; BEVACIZUMAB; BIOLOGICAL MARKER; CALCIUM; CARBAMAZEPINE; CARBOPLATIN; CISPLATIN; ERYTHROPOIETIN; ETOPOSIDE; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; LEVACECARNINE; MAGNESIUM; NAVELBINE; NEUROPROTECTIVE AGENT; NIMODIPINE; OXALIPLATIN; PACLITAXEL; PLATINUM; XALIPRODEN;

ANEMIA; ANTINEOPLASTIC ACTIVITY; BLOOD TOXICITY; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER PATIENT; CLINICAL TRIAL; COLORECTAL CANCER; DNA REPAIR; DRUG DISPOSITION; DRUG EFFICACY; DRUG MECHANISM; DRUG RESPONSE; DRUG WITHDRAWAL; GASTROINTESTINAL TOXICITY; GENETIC MARKER; GLOMERULUS FILTRATION RATE; HEAD AND NECK CANCER; HEARING LOSS; HUMAN; KIDNEY TUBULE DISORDER; LUNG CANCER; MARKER GENE; NAUSEA; NAUSEA AND VOMITING; NEPHROTOXICITY; NEUROTOXICITY; NEUTROPENIA; NONHUMAN; OTOTOXICITY; OVARY CANCER; PARESTHESIA; PERIPHERAL NEUROPATHY; PHARMACOGENETICS; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; THROMBOCYTOPENIA; UROGENITAL TRACT CANCER; VOMITING;

ANIMALS; DNA REPAIR; DRUG RESISTANCE; GENOME; HUMANS; NERVOUS SYSTEM DISEASES; PHARMACOGENETICS; PLATINUM COMPOUNDS;

EID: 58149484793     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-08-0840     Document Type: Review

References (71)

1. Higby DJ,Wallac e HJ,Jr.,Albert DJ, Holland JF. Diaminodichloroplatinum: a phase I study showing responses in testicular and other tumors. Cancer 1974;33:1219-5.
2. Seiwert TY,Salama JK,Vokes EE. The chemoradiation paradigm in head and neck cancer. Nat Clin Pract Oncol 2007;4:156-71.
3. Ardizzoni A, Boni L,Tiseo M, et al. Cisplatin- versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: an individual patient data meta-analysis. J Natl Cancer Inst 2007;99:847-57.
4. Hess LM, Benham-Hutchins M, Herzog TJ, et al. A meta-analysis of the efficacy of intraperitoneal cisplatin for the front-line treatment of ovarian cancer. Int J Gynecol Cancer 2007;17:561-70.
5. Rajeswaran A, Trojan A, Burnand B, Giannelli M. Efficacy and side effects of cisplatin- and carboplatin-based doublet chemotherapeutic regimens versus non-platinum-based doublet chemotherapeutic regimens as first line treatment of metastatic non-small cell lung carcinoma: a systematic review of randomized controlled trials. Lung Cancer 2008;59:1-11.
6. de Cos Escuin JS, Delgado IU, Rodriguez JC, Lopez MJ, Vicente CD, Miranda JA. [Stage IIIA and IIIB non-small cell lung cancer: results of chemotherapy combined with radiation therapy and analysis of prognostic factors]. Arch Bronconeumol 2007;43:358-65.
7. Helbekkmo N, Sundstrom SH, Aasebo U, et al. Vinorelbine/carboplatin vs gemcitabine/carboplatin in advanced NSCLC shows similar efficacy, but different impact of toxicity. Br J Cancer 2007;97:283-9.
8. Abratt RP, Hart GJ. 10-year update on chemotherapy for non-small cell lung cancer. Ann Oncol 2006;17 Suppl 5:v33-6.
9. Goldberg RM, Sargent DJ, Morton RF, et al. A randomized controlled trial of fluorouracil plus leucovorin,irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2004;22:23-30.
10. Falcone A, Ricci S, Brunetti I, et al. Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. J Clin Oncol 2007;25:1670-6.
11. Ibrahim A, Hirschfeld S, Cohen MH, Griebel DJ, Williams GA, Pazdur R. FDA drug approval summaries: oxaliplatin. Oncologist 2004;9:8-12.
12. Ashley AC, Sargent DJ, Alberts SR, et al. Updated efficacy and toxicity analysis of irinotecan and oxaliplatin (IROX): intergroup trial N9741 in first-line treatment of metastatic colorectal cancer. Cancer 2007;110:670-7.
13. McKeage MJ. Comparative adverse effect profiles of platinum drugs. Drug Saf 1995;13:228-44.
14. Barrett SV, Paul J, Hay A, Vasey PA, Kaye SB, Glasspool RM. Does body mass index affect progression-free or overall survival in patients with ovarian cancer? Results from SCOTROC I trial. Ann Oncol 2008;19:898-902.
15. Ekhart C, de Jonge ME, Huitema AD, Schellens JH, Rodenhuis S, Beijnen JH. Flat dosing of carboplatin is justified in adult patients with normal renal function. Clin Cancer Res 2006;12:6502-8.
16. Chaney SG, Campbell SL, Bass ett E, Wu Y. Recognition and processing of cisplatin- and oxaliplatin-DNA adducts. Crit Rev Oncol Hematol 2005;53:3-11.
17. Wang D, Lippard SJ. Cellular processing of platinum anticancer drugs. Nat Rev Drug Discov 2005;4:307-20.
18. Kartalou M, Essigmann JM. Recognition of cisplatin adducts by cellular proteins. Mutat Res 2001;478:1-21.
19. Cavaletti G, Tredici G, Petruccioli MG, et al. Effects of different schedules of oxaliplatin treatment on the peripheral nervous system of the rat. Eur J Cancer 2001;37:2457-63.
20. Krishnan AV, Goldstein D, Friedlander M, Kiernan MC. Oxaliplatin-induced neurotoxicity and the development of neuropathy. Muscle Nerve 2005;32:51-60.
21. Windebank AJ, Grisold W. Chemotherapy-induced neuropathy. J Peripher Nerv Syst 2008;13:27-46.
22. Hah SS, Stivers KM, de Vere White RW, Henderson PT. Kinetics of carboplatin-DNA binding in genomic DNA and bladder cancer cells as determined by accelerator mass spectrometry. Chem Res Toxicol 2006;19:622-6.
23. Zhu C, Raber J, Eriksson LA. Hydrolysis process of the second generation platinum-based anticancer drug cis-amminedichlorocyclohexylamineplatinum(II). J Phys Chem B 2005;109:12195-205.
24. Dzagnidze A, Katsarava Z, Makhalo va J, et al. Repair capacity for platinum-DNA adducts determines the severity of cisplatin-induced peripheral neuropathy. J Neurosci 2007;27:9451-7.
25. Chvalova K, Brabec V, Kasparkova J. Mechanism of the formation of DNA-protein cross-links by antitumor cisplatin. Nucleic Acids Res 2007; 35:1812-21.
26. Stillman M, Cata JP. Management of chemotherapy-induced peripheral neuropathy. Curr Pain Headache Rep 2006;10:279-87.
27. Dunlap B, Paice JA. Chemotherapy-induced peripheral neuropathy: a need for standardization in measurement. J Support Oncol 2006;4:398-9.
28. Sul JK, Deangelis LM. Neurologic complications of cancer chemotherapy. Semin Oncol 2006;33:324-32.
29. McKeage MJ, Hsu T, Screnci D, Haddad G, Baguley BC. Nucleolar damage correlates with neurotoxicity induced by different platinum drugs. Br J Cancer 2001;85:1219-25.
30. Safaei R. Role of copper transporters in the uptake and efflux of platinum containing drugs. Cancer Lett 2006;234:34-9.
31. McDonald ES, Randon KR, Knight A, Windebank AJ. Cisplatin preferentially binds to DNA in dorsal root ganglion neurons in vitro and in vivo: a potential mechanism for neurotoxicity. Neurobiol Dis 2005;18:305-13.
32. Ta LE, Espeset L, Podratz J, Windebank AJ. Neurotoxicity of oxaliplatin and cisplatin for dorsal root ganglion neurons correlates with platinum-DNA binding. Neurotoxicology 2006;27:992-1002.
33. Suk R, Gurubhagavatula S, Park S, et al. Polymorphisms in ERCC1 and grade 3 or 4 toxicity in non-small cell lung cancer patients. Clin Cancer Res 2005;11:1534-8.
34. Raymond E, Faivre S, Woynarowski JM, Chaney SG. Oxaliplatin: mechanism of action and antineoplastic activity. Semin Oncol 1998;25:4-12.
35. Bianchi R, Brines M, Lauria G, et al. Protective effect of erythropoietin and its carbamylated derivative in experimental cisplatin peripheral neurotoxicity. Clin Cancer Res 2006;12:2607-12.
36. DiPaola RS, Schuchte r L. Neurologic protection by amifostine. Semin Oncol 1999;26:82-8.
37. Lersch C, Schmelz R, Eckel F, et al. Prevention of oxaliplatin-induced peripheral sensory neuropathy by carbamazepine in patients with advanced colorectal cancer. Clin Colorectal Cancer 2002;2:54-8.
38. Hochster HS, Grothey A, Childs BH. Use of calcium and magnesium salts to reduce oxaliplatin-related neurotoxicity. J Clin Oncol 2007;25:4028-9.
39. De Grandis D. Acetyl-L-carnitine for the treatment of chemotherapy-induced peripheral neuropathy: a short review. CNS Drugs 2007;21 Suppl 1:39-43; discussion 5-6.
40. Susman E. Xaliproden lessens oxaliplatin-mediated neuropathy. Lancet Oncol 2006;7:288.
41. Schmidinger M, Budinsky AC, Wenzel C, et al. Glutathione in the prevention of cisplatin induced toxicities. A prospectively randomized pilot trial in patients with head and neck cancer and non small cell lung cancer. Wien Klin Wochenschr 2000;112:617-23.
42. Cascinu S, Catalano V, Cordella L, et al. Neuroprotective effect of reduced glutathione on oxaliplatin-based chemotherapy in advanced colorectal cancer: a randomized, double-blind, placebo-controlled trial. J Clin Oncol 2002;20:3478-83.
43. van der Hoop RG, Vecht CJ,van der Burg ME, et al. Prevention of cisplatin neurotoxicity with an ACTH(4-9) analogue in patients with ovarian cancer. N Engl J Med 1990;322:89-94.
44. Albers J, Chaudhry V, Cavaletti G, Donehower R. Interventions for preventing neuropathy caused by cisplatin and related compounds. Cochrane Database Syst Rev 2007 CD005228.
45. Cavaletti G, Bogliun G, Marzorati L, et al. Early predictors of peripheral neurotoxicity in cisplatin and paclitaxel combination chemotherapy. Ann Oncol 2004;15:1439-42.
46. Mileshkin L, Stark R, Day B, Seymour JF, Zeldis JB, Prince HM. Development of neuropathy in patients with myeloma treated with thalidomide: patterns of occurrence and the role of electrophysiologic monitoring. J Clin Oncol 2006;24:4507-14.
47. Potti A, Dressman HK, Bild A, et al. Genomic signatures to guide the use of chemotherapeutics. Nat Med 2006;12:1294-300.
48. Ruzzo A, Graziano F, Loupakis F, et al. Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFOX-4 chemotherapy. J Clin Oncol 2007;25:1247-54.
49. Lecomte T, Landi B, Beaune P, Laurent-Puig P, Loriot MA. Glutathione S-transferase P1 polymorphism (Ile 105Val) predicts cumulative neuropathy in patients receiving oxaliplatin-based chemotherapy. Clin Cancer Res 2006;12:3050-6.
50. Pillot GA, Read WL, Hennenfent KL, et al. A phase II study of irinotecan and carboplatin in advanced non-small cell lung cancer with pharmacogenomic analysis: final report. J Thorac Oncol 2006;1:972-8.
51. Gamelin L, Capitain O, Morel A, et al. Predictive factors of oxaliplatin neurotoxicity: the involvement of the oxalate outcome pathway. Clin Cancer Res 2007;13:6359-68.
52. Ishida S, Lee J,Thiele DJ, Herskowitz I. Uptake of the anticancer drug cisplatin mediated by the copper transporter Ctr1 in yeast and mammals. Proc Natl Acad Sci U S A 2002;99:14298-302.
53. Yuan P, Miao XP, Zhang XM, et al. [Polymorphisms in nucleotide excision repair genes XPC and XPD and clinical responses to platinum-based chemotherapy in advanced non-small cell lung cancer]. Zhonghua Yi Xue Za Zhi 2005;85:972-5.
54. Park DJ, Zhang W, Stoehlmacher J,et al. ERCC1 gene polymorphism as a predictor for clinical outcome in advanced colorectal cancer patients treated with platinum-based chemotherapy. Clin Adv Hematol Oncol 2003;1:162-6.
55. Kang S, Ju W, Kim JW, et al. Association between excision repair cross-complementation group 1 polymorphism and clinical outcome of platinum-based chemotherapy in patients with epithelial ovarian cancer. Exp Mol Med 2006;38:320-4.
56. Mori T, Hosokawa K, Kinoshita Y, et al. A pilot study of docetaxelcarboplatin versus paclitaxel-carboplatin in Japanese patients with epithelial ovarian cancer. Int J Clin Oncol 2007;12:205-11.
57. Marsh S, Paul J, King CR, Gifford G, McLeod HL, Brown R. Pharmacogenetic assessment of toxicity and outcome after platinum plus taxane chemotherapy in ovarian cancer: the Scottish Randomised Trial in Ovarian Cancer. J Clin Oncol 2007;25:4528-35.
58. Nagashima F, Zhang W, Yang D, et al. Polymorphism in sodium-channel α 1-subunit (SCN1A) predicts response, TTP, survival, and toxicity in patients with metastatic colorectal cancer treated with 5-FU/ oxaliplatin. In: Journal of Clinical Oncology, 2006 ASCO Annual Meeting Proceedings Part I; 2006 Jun 2-6; Atlanta, Georgia. p.3533.
59. Caruba T, Cottu PH, Madelaine-Chambrin I, Espie M, Misset JL, Gross-Goupil M. Gemcitabine-oxaliplatin combination in heavily pretreated metastatic breast cancer: a pilot study on 43 patients. Breast J 2007;13:165-71.
60. Ferrero JM, Weber B, Geay JF, et al. Second-line chemotherapy with pegylated liposomal doxorubicin and carboplatin is highly effective in patients with advanced ovarian cancer in late relapse: a GINECO phase II trial. Ann Oncol 2007;18:263-8.
61. Choi CH, Kim TJ, Lee SJ, et al. Salvage chemotherapy with a combination of paclitaxel, ifosfamide, and cisplatin for the patients with recurrent carcinoma of the uterine cervix. Int J Gynecol Cancer 2006;16:1157-64.
62. Belani CP, Fossella F. Elderly subgroup analysis of a randomized phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for first-line treatment of advanced nonsmall cell lung carcinoma (TAX 326). Cancer 2005;104:2766-74.
63. Mardiak J, Salek T, Sycova-Mila Z, et al. Gemcitabine plus cisplatine and paclitaxel (GCP) in second-line treatment of germ cell tumors (GCT): a phase II study. Neoplasma 2005;52:243-7.
64. Pfisterer J, Plante M, Vergote I, et al. Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG. J Clin Oncol 2006;24:4699-707.
65. Pujol JL, Milleron B, Molinier O, et al. Weekly paclitaxel combined with monthly carboplatin in elderly patients with advanced non-small cell lung cancer: a multicenter phase II study. J Thorac Oncol 2006;1:328-34.
66. Robert N, Leyland-Jones B, Asmar L, et al. Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2-overexpressing metastatic breast cancer. J Clin Oncol 2006;24:2786-92.
67. Kakolyris S, Ziras N, Vamvakas L, et al. Gemcitabine plus oxaliplatin combination (GEMOX regimen) in pretreated patients with advanced non-small cell lung cancer (NSCLC): a multicenter phase II study. Lung Cancer 2006;54:347-52.
68. Fracasso PM, Blessing JA, Molpus KL, Adler LM, Sorosky JI, Rose PG. Phase II study of oxaliplatin as second-line chemotherapy in endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 2006;103:523-6.
69. Cappuzzo F, Novello S, De Marinis F, et al. Phase II study of gemcitabine plus oxaliplatin as first-line chemotherapy for advanced non-small-cell lung cancer. Br J Cancer 2005;93:29-34.
70. Steer CB, Chrystal K, Cheong KA, et al. Gemcitabine and oxaliplatin followed by paclitaxel and carboplatin as first line therapy for patients with suboptimally debulked, advanced epithelial ovarian cancer. A phase II trial of sequential doublets. The GO-First Study. Gynecol Oncol 2006;103:439-45.
71. Delaloge S, Laade m A, Taamma A, et al. Pilot study of the paclitaxel, oxaliplatin, and cisplatin combination in patients with advanced/recurrent ovarian cancer. Am J Clin Oncol 2000;23:569-74.